ConductScience.org, home

Gene · 79679

VTCN1: V-set domain containing T cell activation inhibitor 1

12 sourcesgene-search-2026-11-11-0.2.0

Download JSON
Cite this record

ConductScience Library. VTCN1: V-set domain containing T cell activation inhibitor 1. Genes, record 79679. Release gene-search-2026-11-11-0.2.0, 11 Nov 2026. https://conductscience.org/library/genes/79679

On this page

Gene

Symbol
VTCN1
HGNC
Name
V-set domain containing T cell activation inhibitor 1
HGNC
NCBI Gene ID
79679
NCBI Gene
HGNC ID
HGNC:28873
HGNC
Ensembl
ENSG00000134258
NCBI Gene
Aliases
B7-H4, B7H4, B7S1, B7X, B7h.5, B7x, FLJ22418, PRO1291, VCTN1
NCBI Gene
Type
protein-coding
NCBI Gene

Proteins1

Reviewed human proteins whose Swiss-Prot entry states the gene.

UniProt entryProteinLengthStructuresGene stated in
Q7Z7D3V-set domain-containing T-cell activation inhibitor 12821Ensembl, GeneID, HGNC

Source UniProt

Patents499

Patents whose sequence listing contains this protein's exact sequence. A patent can list a sequence without claiming it.

PublicationPublishedSEQ ID NOProteinSource
EP 4831196 A22026-10-287Q7Z7D3Espacenet
EP 4824100 A22026-10-211Q7Z7D3Espacenet
WO 2026151884 A12026-07-161Q7Z7D3Espacenet
JP 2026090543 A2026-06-02180Q7Z7D3Espacenet
JP 2026082984 A2026-05-1959Q7Z7D3Espacenet
US 12624087 B22026-05-127Q7Z7D3Espacenet
US 12612446 B22026-04-28449Q7Z7D3Espacenet
JP 2026053725 A2026-03-251Q7Z7D3Espacenet
JP 2025166053 A2025-11-057Q7Z7D3Espacenet
JP 2025148471 A2025-10-07449Q7Z7D3Espacenet

1 to 10 of 499

See all 499 patents

Drugs0

Drugs a ChEMBL mechanism record says act on the gene's protein, through Open Targets.

None in this release.

Trials0

Trials of those drugs. A trial joins the gene only through a drug that acts on it.

None in this release.

NIH grants878

NIH grants whose papers are about the gene, through NIH's grant-paper links.

GrantTitleVTCN1 papersNewest fiscal year
P30CA016672Cancer Center Support Grant182025
P30CA016359Cancer Center Support Grant172025
R01CA175495The B7x pathways in the tumor microenvironment152025
P30CA008748Cancer Center Support Grant112025
P30CA013330Cancer Center Support Grant112025
P50CA196530Yale SPORE in Lung Cancer (YSILC): The Biology and Personalized Treatment of Lung Cancer102025
P30CA006973Regional Oncology Research Center82025
P50CA101942DF/HCC Kidney Cancer SPORE (supplement)62025
UL1TR001863Yale Clinical and Translational Science Award62025
P50CA121974Yale SPORE in Skin Cancer52025

1 to 10 of 878Source NIH's project files

See all 878 nih grants

Papers2,409

Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.

TitleJournalYearPMIDFound bySource
[Special tumor entities : New results at the 2026 ASCO Annual Meeting].HNO202642814119PubTator, text miningPubMed
Time to Rethink Pathology Reporting in Adenoid Cystic Carcinoma.Head Neck202642811719PubTator, text miningPubMed
A study on the mechanism of action of B7H4 in HER2-positive gastric cancer and its sensitivity to trastuzumab therapy.Transl Cancer Res202642724573PubTator, text miningPubMed
Membrane and soluble VTCN1 (B7H4) converge on Src signaling to mediate gemcitabine resistance in intrahepatic cholangiocarcinoma.Theranostics202642708082PubTator, text miningPubMed
Pre-treatment T-cell Transcriptional Signatures Predict Immunotherapy Outcomes in Melanoma.Res Sq202642687902PubTator, text miningPubMed
Nardilysin: classical functions and new horizons in autoimmunity.Front Immunol202642676835PubTator, text miningPubMed
AI-enabled discovery and biochemical optimization of minibinders targeting cancer cell-surface proteins.Nat Commun202642624861PubTator, text miningPubMed
European Society for Medical Oncology Gynaecological Cancers Congress 2026: key scientific advances from the oral sessions.Int J Gynecol Cancer202642624675PubTator, text miningPubMed
B7-H4 enrichment represents a site-specific immunotherapy target in small bowel gastrointestinal stromal tumors.bioRxiv202642620335PubTator, text miningPubMed
Antibody drug conjugates in gynaecological cancers: navigating between opportunities and challenges.EClinicalMedicine202642534594PubTator, text miningPubMed

1 to 10 of 2,409

See all 2,409 papers

Sources 12

  • ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
  • GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
  • HGNCCC0
  • NCBI GenePublic domain (US government)
  • NIH's project files and grant-paper linksPublic domain
  • Open TargetsCC0 1.0
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
  • GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
  • HGNCCC0: https://www.genenames.org/about/license/
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this gene from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/genes/v1/79679

GET https://conductscience.org/api/genes/v1/79679/patents?page=2